![](/img/cover-not-exists.png)
Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes
Campbell-Scherer, DeniseVolume:
22
Language:
english
Journal:
Evidence Based Medicine
DOI:
10.1136/ebmed-2016-110652
Date:
April, 2017
File:
PDF, 97 KB
english, 2017